EGFR and neoplasm: Cetuximab, an approved monoclonal antibody to target epidermal growth factor receptor (EGFR) in colorectal cancer, has been shown to upregulate phagocytosis of EGFR overexpressing cancer cells, leading to enhanced T-cell-mediated anti-tumor immune response [70].